J.PaulMonkIIIMD

Oncology • Columbus, OH

medical Oncologist and an assistant professor in the Department of Internal Medicine At the OSUCCC

Join to view full profile

Dr. Monk is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Monk's full profile

Already have an account?

Office
300 W 10th Ave
1st Floor
Columbus, OH 43210
Phone+1 614-293-6196

Fax+1 614-366-0073
Is this information wrong?

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1999 - 2002
OhioHealth/Riverside Methodist HospitalResidency, Internal Medicine, 1996 - 1999
Ohio State University College of MedicineClass of 1996

Certifications & Licensure

OH State Medical License 1999 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma Start of enrollment: 2006 Nov 08
Completed
Phase 1
Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer Start of enrollment: 2008 Feb 01
Terminated
Phase 2
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2009 Oct 29
Active, not recruiting
Phase 1, Phase 2
Tivantinib in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2012 Jan 11
Completed
Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Prog...
Wassim Abida, Andrew W Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber, Matthew R Smith, Tanya Dorff, Paul Monk, Matthew Rettig, Rupal Patel, Anne Page, Maureen Duff, Ro...> ;Clinical Cancer Research. 2024 Mar 15
Chemotherapy for the initial treatment of metastatic prostate adenocarcinoma and neuroendocrine carcinoma at diagnosis: real world application and impact in the SEER d...
Shihua Wang, Ming Yin, Peng Wang, Edmund Folefac, J Paul Monk, Fred K Tabung, Steven K Clinton> ;Frontiers in Oncology. 2023 Jan 1
44 citations
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
James A. Eastham, Glenn Heller, Susan Halabi, J. Paul Monk, Himisha Beltran, Martin E. Gleave, Christopher P. Evans, Steven K. Clinton, Russell Z. Szmulewitz, Jonathan...> ;Journal of Clinical Oncology. 2020 Jul 24
3 citations
Effects of a lifestyle intervention on body composition in prostate cancer patients on androgen deprivation therapy.
Zachary L Chaplow, Brian C Focht, Alexander R Lucas, Elizabeth Grainger, Christina Simpson, Jackie Buell, Ciaran M Fairman, Jennifer M Thomas-Ahner, Jessica Bowman, Vi...> ;JCSM Clinical Reports. 2020 Apr 1
8 citations
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Ca...
Elisabeth I. Heath, Lance K. Heilbrun, Heather D. Mannuel, Glenn Liu, Primo N. Lara, J. Paul Monk, Thomas W. Flaig, Amado J. Zurita, Philip C. Mack, Ulka N. Vaishampay...> ;The Oncologist. 2019 Sep 1
5 citations
Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.
Melanie A. Krook, Hannah Barker, Hui-Zi Chen, Julie W. Reeser, Michele R. Wing, Dorrelyn Martin, Amy M. Smith, Thuy Dao, Russell Bonneville, Eric Samorodnitsky, Jharna...> ;Prostate Cancer and Prostatic Diseases. 2019 May 1
34 citations
Effects of a Group-Mediated Exercise and Dietary Intervention in the Treatment of Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Results From the ID...
Brian C. Focht, Alexander R. Lucas, Elizabeth Grainger, Christina Simpson, Ciaran M. Fairman, Jennifer M. Thomas-Ahner, Jackie Buell, J. Paul Monk, Amir Mortazavi, Ste...> ;Annals of Behavioral Medicine. 2018 Apr 19
61 citations
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).
Roberto Pili, David I. Quinn, Hans J. Hammers, J. Paul Monk, Saby George, Tanya B. Dorff, Thomas Olencki, Li Shen, Ashley Orillion, Dominick Lamonica, Roberto A. Salas...> ;Clinical Cancer Research. 2017 Dec 1
6 citations
Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer
Michele R. Wing, Julie W. Reeser, Amy M. Smith, Matthew Reeder, Dorrelyn Martin, Benjamin M. Jewell, Jharna Datta, Jharna Miya, J. Paul Monk, Amir Mortazavi, Gregory A...> ;Oncotarget. 2017 Sep 2
4 citations
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421
Guru Sonpavde, Gregory R. Pond, Melissa Plets, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Amir Goldkorn, Mark Garzotto, Philip C. Mack, Celestia S. Higano, Nich...> ;Clinical Genitourinary Cancer. 2016 May 20
22 citations
The Raf Kinase Inhibitor Sorafenib Inhibits JAK–STAT Signal Transduction in Human Immune Cells
Sara E. Martin del Campo, Kala M. Levine, Bethany L. Mundy-Bosse, Valerie P. Grignol, Ene T. Fairchild, Amanda Campbell, Prashant Trikha, Thomas A. Mace, Bonnie Paul, ...> ;Journal of Immunology. 2015 Sep 1
35 citations
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial
Amir Goldkorn, Benjamin Ely, Catherine M. Tangen, Yu-Chong Tai, Tong Xu, Hongli Li, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael A. Carducci...> ;International Journal of Cancer. 2015 Apr 15
5 citations
Real-Time Scintigraphic Assessment of Intravenous Radium-223 Administration for Quality Control
Chadwick Wright, J. Paul Monk, Douglas A Murrey, Nathan Hall> ;Biomed Research International. 2015 Feb 18
215 citations
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Res...
Amir Goldkorn, Benjamin Ely, David I. Quinn, Catherine M. Tangen, Louis M. Fink, Tong Xu, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael A. Ca...> ;Journal of Clinical Oncology. 2014 Apr 10
185 citations
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)
Matthew R. Smith, Susan Halabi, Charles J. Ryan, Arif Hussain, Nicholas A. Vogelzang, Walter M. Stadler, Ralph J. Hauke, J. Paul Monk, Philip J. Saylor, Nirmala Bhoopa...> ;Journal of Clinical Oncology. 2014 Apr 10
20 citations
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: resu...
Rahul Aggarwal, Susan Halabi, William Kevin Kelly, Daniel J. George, John Francis Mahoney, Frederick Millard, Walter M. Stadler, Michael J. Morris, Philip W. Kantoff, ...> ;Cancer. 2013 Oct 15
120 citations
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
David I. Quinn, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Amir Goldkorn, Carol M. Moinpour, Mark Garzotto, Philip C. Mack, Michael A. Carducci, J. Paul Monk, P...> ;The Lancet. Oncology. 2013 Aug 1
24 citations
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
Amir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, Lai Wei, Mitch A. Phelps, Zhongfa Liu, Erica Harper, S. Percy Ivy, Xin Wu, Bing Sen Zhou, Xiyong Liu, Deidre De...> ;Investigational New Drugs. 2013 Jun 1
17 citations
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (C...
J. Paul Monk, Susan Halabi, Joel Picus, Arif Hussain, George Philips, Ellen B. Kaplan, Tim A. Ahles, Lin Gu, Nicholas J. Vogelzang, William Kevin Kelly, Eric J. Small> ;Cancer. 2012 Sep 1
3 citations
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors.
J. Paul Monk, Miguel A. Villalona-Calero, Joe Larkin, Greg Otterson, David S. Spriggs, Alison L. Hannah, G. F. Cropp, Robert Johnson, Martee L. Hensley> ;Investigational New Drugs. 2012 Aug 1
363 citations
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant...
William Kevin Kelly, Susan Halabi, Michael A. Carducci, Daniel J. George, John Francis Mahoney, Walter M. Stadler, Michael J. Morris, Philip W. Kantoff, J. Paul Monk, ...> ;Journal of Clinical Oncology. 2012 May 1
Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasiv...
Mitra N, Monk JP, Pohar KS, Shabsigh A, Sharp DS, Abaza R, Box GN, Zynger DL, Vandlik SL, Bhinder AS, Olencki T, Bahnson RR, Clinton SK, Mortazavi A> ;J. Clin. Oncol.. 2011-05-20
Bevacizumab in metastatic papillary renal cell carcinoma (PRCC).
Irshad T, Olencki T, Zynger DL, Coston A, Mortazavi A, Monk JP> ;J. Clin. Oncol.. 2011-05-20
Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma.
Lam ET, Wong MKK, Agarwal N, Redman BG, Logan T, Flaig TW, Monk JP, Jarkowski A, Sendilnathan A, Bolden M, Kuzel T, Olencki T> ;J. Clin. Oncol.. 2011-05-20
Phase I study of high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma.
Lam ET, Lesinski G, Mortazavi A, Kendra KL, Carson WE, Tahiri S, Liersemann R, Clinton SK, Olencki T, Monk JP> ;J. Clin. Oncol.. 2011-03-01
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Ohio State University Wexner Medical CenterColumbus, Ohio
The OSUCCC - JamesColumbus, Ohio